四川大学学报（医学版）2023，Vol.54Issue(6)：1065-1073,9.DOI:10.12182/20231160108
TGF-β1/SMAD在糖尿病肾病中的作用机制与研究进展
The Role of TGF-β1/SMAD in Diabetic Nephropathy:Mechanisms and Research Development
摘要
Abstract
Diabetic nephropathy(DN)is a common complication of diabetes and a leading cause of end-stage renal disease.Transforming growth factor-β1(TGF-β1)/SMAD signaling activation plays an important role in the onset and progression of DN.Reported findings suggest that the activation of TGF-β1(including the latent form,the active form,and the receptors)and its downstream signaling proteins(SMAD3,SMAD7,etc.)plays a critical role in DN.In addition,TGF-β1/SMAD signaling may mediate the pathogenesis and progression of DN via various microRNAs(miRNAs)and long non-coding RNAs(lncRNAs).Emerging evidence shows that TGF-β1,SMAD3,and SMAD7 are the main signaling proteins that contribute to the development of DN,and that they can be potential targets for the treatment of DN.However,recent clinical trials have shown that the anti-TGF-β1 monoclonal antibody treatment fails to effectively alleviate DN,which suggests that upstream inhibition of TGF-β1/SMAD signaling does not alleviate clinical symptoms and that this may be related to the fact that TGF-β1/SMAD has multiple biological effects.Targeted inhibition of the downstream TGF-β1 signaling(e.g.,SMAD3 and SMAD7)may be an effective approach to attenuate DN.This article discussed the current understanding of the molecular mechanisms and potential targets for the treatment and prevention of DN by focusing on TGF-β1/SMAD signaling.关键词
糖尿病肾病/转化生长因子-β1/SMAD/糖尿病/微RNA/长链非编码RNA/综述Key words
Diabetic nephropathy/TGF-β1/SMAD/Diabetes mellitus/miRNA/lncRNA/Review引用本文复制引用
王一帆,郭建波,邵宝仪,陈海勇,蓝辉耀..TGF-β1/SMAD在糖尿病肾病中的作用机制与研究进展[J].四川大学学报（医学版）,2023,54(6):1065-1073,9.基金项目
香港优配研究基金(No.GRF 17125323)和深圳科创委基础研究面上项目(No.JCYJ20210324114604013)资助 （No.GRF 17125323）
